Join to invest

Already registered? Log in

172%

The success rate for cancer drug development is ~5%. Imagen has pioneered an automated, sophisticated algorithmic technique - to date modelling >150,000 patient treatment data points, which is now being used to accelerate the drug development process and reduce failure. Historically ~£3m raised.

  • Founded and led by ex-AstraZeneca scientist in cell biology
  • Building unique biobank via unparalleled access to patients and data
  • Advisors from Imperial (London), Christie Hospital (Manchester) & big pharma 
  • Oncology is largest global pharma market (~$200 billion by 2026)
Information Imagen Therapeutics has previously issued £353,150.70 worth of shares and this is reflected on the pitch progress bar for clarity. The company has not spent these funds at the date the pitch went live.

Idea

We aim to benefit patients by revolutionising cancer research for pharma.

Our unique innovative platform aims to identify the most effective cancer treatments, helping to deliver personalised, life-changing medicines.

Every cancer is genetically unique, making it difficult for oncologists to predict which treatments to select & which to avoid. Imagen can test 1000's of individual tumours across a wide range of cancer drugs in-vitro, aiming to predict which are most likely to be effective.

Imagen has fully developed its proprietary predictRx assay, enabling oncologists to refer patients to Imagen. This is creating a source of tumour samples to which industry does not have access, allowing Imagen to expand into the pharma sector by satisfying its unmet demand for patient-derived cancer models.

In early-stage drug development, companies must use pre-clinical 'models' that closely resemble real patients, but few such models with patient-relevant data are available. This scarcity contributes to the high drug development failure rate (~95%), which Imagen is addressing by developing 1000's of patient-derived cancer models using its global access to patients.

We require capital to scale our infrastructure with the aim of creating the world's leading Biobank of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Imagen pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Imagen has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.